For a patient currently taking oxycodone‑acetaminophen 5‑325 mg tablet every 8 hours for pain, how should the opioid be tapered and what orders should be placed?

Opioid Tapering Strategy for Oxycodone-Acetaminophen 5-325 mg

For a patient on oxycodone-acetaminophen 5-325 mg every 8 hours (15 mg oxycodone/day), initiate a slow taper by reducing the dose by 10% of the current dose every 2-4 weeks, which translates to reducing by approximately 0.5 mg oxycodone per step, requiring close monthly monitoring and optimization of non-opioid pain therapies. 1, 2

Specific Tapering Orders

Initial Assessment & Shared Decision-Making

Before ordering any taper, you must:

• Engage the patient in shared decision-making about tapering goals and timeline 1
• Assess duration of opioid use (if ≥1 year, expect a slower, longer taper) 1
• Screen for anxiety, depression, and opioid use disorder 1
• Prescribe naloxone for overdose reversal education 2

Concrete Tapering Schedule

Current dose: Oxycodone-acetaminophen 5-325 mg every 8 hours = 15 mg oxycodone/day

Recommended taper rate: 10% per month (or slower) for long-term users 1

Step-by-Step Orders:

Month 1-2:

• Order: Oxycodone-acetaminophen 5-325 mg: Take 1 tablet at 8am and 8pm, then ½ tablet at 4am (or skip one dose entirely)
• This reduces daily dose to approximately 12.5-13 mg/day (10-15% reduction)

Month 3-4:

• Order: Oxycodone-acetaminophen 2.5-325 mg: Take 1 tablet every 8 hours
• This reduces to 7.5 mg oxycodone/day (50% reduction from baseline)

Month 5-6:

• Order: Oxycodone-acetaminophen 2.5-325 mg: Take 1 tablet twice daily (every 12 hours)
• This reduces to 5 mg oxycodone/day

Month 7-8:

• Order: Oxycodone-acetaminophen 2.5-325 mg: Take 1 tablet once daily
• This reduces to 2.5 mg oxycodone/day

Month 9-10:

• Order: Oxycodone-acetaminophen 2.5-325 mg: Take 1 tablet every other day
• Then extend to every 3 days, then discontinue 1

Critical Monitoring Requirements

Monthly follow-up visits are mandatory 1. At each visit assess:

• Withdrawal symptoms: anxiety, insomnia, abdominal pain, vomiting, diarrhea, sweating, dilated pupils, tremor, rapid heart rate 1
• Pain levels (may temporarily increase initially but often improve or remain stable after completion) 3
• Mental health status (depression, suicidal ideation) 1
• Signs of opioid use disorder 1

Adjunctive Orders

Optimize non-opioid therapies concurrently 1:

• NSAIDs (if not contraindicated)
• Acetaminophen (monitor total daily dose <4g including combination product)
• Gabapentinoids for neuropathic pain
• Topical analgesics
• Physical therapy referral
• Consider cognitive behavioral therapy for chronic pain 4

For withdrawal symptom management 5:

• Clonidine 0.1-0.2 mg every 6-8 hours PRN for autonomic symptoms
• Ondansetron 4-8 mg every 8 hours PRN for nausea
• Loperamide 2-4 mg PRN for diarrhea
• Hydroxyzine 25-50 mg every 6 hours PRN for anxiety/insomnia

Critical Pitfalls to Avoid

Never abruptly discontinue - this causes serious withdrawal, uncontrolled pain, and has been associated with suicide and overdose from seeking alternative sources 2

If withdrawal symptoms emerge: Pause the taper or slow it further 1. The CDC 2022 guidelines emphasize that 10% per month or slower is better tolerated than faster tapers for long-term users 1.

Beware of protracted withdrawal: Months after cessation, patients may experience dysphoria, irritability, insomnia, anhedonia - these must be anticipated and managed 5

Loss of tolerance risk: Warn patients that returning to previous doses after tapering dramatically increases overdose risk 1

When to Modify This Plan

Slow the taper further if:

• Patient has been on opioids >1 year 1
• Significant withdrawal symptoms develop 1
• Patient struggles with tolerating current taper rate 1

Consider specialist referral if:

• Unable to taper despite optimization 1
• Opioid use disorder identified 2
• Pregnancy (specialized expertise required) 1

The 2022 CDC guidelines 1 and FDA labeling 2 both emphasize that there is no standard tapering schedule suitable for all patients, but the evidence strongly supports slow, gradual tapers (10% per month or slower) with individualized adjustments based on withdrawal symptoms and patient tolerance. Recent research 6 suggests hyperbolic tapering (proportional reductions becoming progressively smaller) may be most pharmacologically rational, though this requires further validation.